Compare Boston Scientific Corporation (BSX) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Ferrari NV — how do they compare? Boston Scientific Corporation trades at $43.49 (market cap $66.37B), while Ferrari NV trades at $376 (market cap $65.00B). The key difference: Boston Scientific Corporation and Ferrari NV are close in size by market cap, and Ferrari NV pays a 1.14% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | RACE | |
|---|---|---|
Market Cap | $66.37B | $65.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $108.14 | $517.65 |
52-Week Low | $42.63 | $314.63 |
Enterprise Value | $75.94B | $66.21B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Ferrari (RACE) trades at $372.98, down 0.97% on the day, with a bullish technical signal supported by moving averages. The stock exhibits strong profitability with a net income margin of 22.19% and robust revenue growth from $5.1B in 2022 to $7.1B in 2025. Recent news highlights the company's ongoing share buyback program and strategic moves in the EV space, though the Luce model has faced some market skepticism.
The outlook remains positive with a consensus price target of $467.50, implying significant upside. Key opportunities include pricing power and margin strength, while risks involve execution on EV strategy and high valuation multiples. Earnings consistently beat expectations, supporting the bullish analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
